Challenge
A clinical-stage biotech company had an ongoing Phase 1 program exploring a combination therapy in multiple cancer types. The company wished to validate the addition of cholangiocarcinoma (CCA) to its list of target indications and commissioned Alacrita to evaluate the therapeutic landscape and market opportunity in CCA to help support its strategy.
Solution
Alacrita performed an extensive literature and database review of the CCA landscape.
We mapped the current treatment pathway, ongoing development pipeline and identified key areas of clinical unmet need.
Additionally, we quantified the available patient population in the US and Europe and summarised possible regulatory benefits afforded to targeting a rare indication. Our findings were detailed in a PowerPoint report and the client was able to evaluate the attractiveness of CCA as a possible target indication.
Opportunity Mapping Services
We can help you gauge and rank the opportunities for your R&D programs or technology platforms to deliver value, by framing the commercial potential and charting the path to market.
Back